These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 38760099)

  • 1. B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases.
    Haghikia A; Schett G; Mougiakakos D
    Lancet Neurol; 2024 Jun; 23(6):615-624. PubMed ID: 38760099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review.
    Konitsioti AM; Prüss H; Laurent S; Fink GR; Heesen C; Warnke C
    J Neurol; 2024 Oct; 271(10):6526-6542. PubMed ID: 39276207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements and challenges in CAR T cell therapy in autoimmune diseases.
    Schett G; Müller F; Taubmann J; Mackensen A; Wang W; Furie RA; Gold R; Haghikia A; Merkel PA; Caricchio R; D'Agostino MA; Locatelli F; June CH; Mougiakakos D
    Nat Rev Rheumatol; 2024 Sep; 20(9):531-544. PubMed ID: 39107407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis.
    Fischbach F; Richter J; Pfeffer LK; Fehse B; Berger SC; Reinhardt S; Kuhle J; Badbaran A; Rathje K; Gagelmann N; Borie D; Seibel J; Ayuk F; Friese MA; Heesen C; Kröger N
    Med; 2024 Jun; 5(6):550-558.e2. PubMed ID: 38554710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?
    Shah K; Leandro M; Cragg M; Kollert F; Schuler F; Klein C; Reddy V
    Clin Exp Immunol; 2024 Jun; 217(1):15-30. PubMed ID: 38642912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells.
    Motte J; Sgodzai M; Schneider-Gold C; Steckel N; Mika T; Hegelmaier T; Borie D; Haghikia A; Mougiakakos D; Schroers R; Gold R
    Neuron; 2024 Jun; 112(11):1757-1763.e2. PubMed ID: 38697115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
    Hunter BD; Rogalski M; Jacobson CA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
    [No Abstract]   [Full Text] [Related]  

  • 9. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
    Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
    Front Immunol; 2021; 12():681984. PubMed ID: 34248965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases.
    Lyu X; Gupta L; Tholouli E; Chinoy H
    Rheumatology (Oxford); 2024 May; 63(5):1206-1216. PubMed ID: 37982747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
    Maus MV; Levine BL
    Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease.
    Daamen AR; Lipsky PE
    Ann Rheum Dis; 2024 May; 83(6):696-699. PubMed ID: 38637134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD19 CAR T cells for multiple sclerosis: Forging further into the new frontier.
    Rankin AW; Shah NN
    Med; 2024 Jun; 5(6):482-484. PubMed ID: 38878763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity.
    Gupta S; Simic M; Sagan SA; Shepherd C; Duecker J; Sobel RA; Dandekar R; Wu GF; Wu W; Pak JE; Hauser SL; Lim W; Wilson MR; Zamvil SS
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36657993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
    Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
    Front Immunol; 2020; 11():594271. PubMed ID: 33224149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.
    Song MK; Park BB; Uhm JE
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31658644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in CAR-T-cell therapy in T-cell malignancies.
    Zheng R; Zhu X; Xiao Y
    J Hematol Oncol; 2024 Jun; 17(1):49. PubMed ID: 38915099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
    Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
    Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.